There are more than 10,000 diseases afflicting humans today, but only five percent of these diseases have approved treatment options. Although spend on pharmaceutical research and development is increasing, 96% of potential drugs never make it to market.

In our 3-part Deep Tech Pharmaceutical Report, we explore:

1. How to reduce the cost of biologics with innovation intelligence
2. The future of adeno-associated virus therapies
3. A deep dive into RNA therapeutics

Each report can be read as a standalone analysis or combined for a more holistic, 360-degree industry overview.

Key Insights:

The AAV technology domain, although niche, has incredible startup attention and venture capital (VC) funding opportunity. Key players include:

• Spark therapeutics
• Regenxbio
• Voyager Therapeutics
• Asklepios Biopharmaceutical
• Rocket Pharmaceuticals

In particular, Regenxbio is very active in protecting its IP, holding 408 patents. The graph below illustrates the company’s patent filing strategy as per specific technology topics and therapeutic intersections.

RNA-related patent applications are increasing year over year, signaling an innovation uptick, as well as a strategic shift in how pharma companies protect their IP.

Unlock key business, IP, and R&D insights with PatSnap, and make more informed innovation decisions

Identify early-stage innovation opportunities

By leveraging different data sources, companies can more accurately validate ideas early on, identify innovation hotspots, and improve their innovation pipeline.

Explore industry trends and competitor portfolio shifts

Using AI-powered technology, companies can stay ahead of competitors, predict and analyze emerging trends, discover new market entrants, and more.

Uncover real-time insights on new research and technology areas

Simplify complex search results, extract key insights, and gain a 360-degree view of a technology area or entire market with Connected Innovation Intelligence.